Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TLSA | US
-0.04
-2.86%
Healthcare
Biotechnology
31/12/2023
02/06/2026
1.36
1.38
1.38
1.31
Tiziana Life Sciences Ltd a biotechnology company focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401) a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's graft versus host ulcerative colitis multiple sclerosis type-1 diabetes inflammatory bowel psoriasis and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201) a small molecule inhibitor of various cyclin-dependent kinases tropomycin receptor kinases and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501) a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London the United Kingdom.Kingdom.
View LessLow Market Beta (-0.4 to 0.8)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
106.2%1 month
82.0%3 months
73.3%6 months
76.5%-
-
16.12
-
-
-5.98
-
-
-15.79M
138.06M
138.06M
-
-
-
-
-181.23
0.29
0.10
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.54
Range1M
0.55
Range3M
0.71
Rel. volume
0.67
Price X volume
224.91K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | GALT | Drug Manufacturers-Specialty & Generic | 2.42 | 150.71M | -7.28% | n/a | -113.78% |
| Adagene Inc. | ADAG | Biotechnology | 3.39 | 150.08M | -10.32% | n/a | 36.29% |
| Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 4.51 | 149.11M | -6.24% | n/a | 6.58% |
| MediWound Ltd | MDWD | Biotechnology | 13.76 | 148.42M | -0.43% | n/a | 0.00% |
| OBIO | OBIO | Biotechnology | 3.91 | 147.89M | 2.09% | n/a | 3.29% |
| Oramed Pharmaceuticals Inc | ORMP | Biotechnology | 3.6 | 146.77M | -7.46% | 4.54 | 0.00% |
| Protalix BioTherapeutics Inc | PLX | Biotechnology | 1.99 | 146.35M | -3.40% | n/a | 91.50% |
| ELEDON PHARMACEUTICALS INC | ELDN | Biotechnology | 3.53 | 146.08M | -6.12% | 6.60 | -7.70% |
| Acumen Pharmaceuticals Inc. Common Stock | ABOS | Biotechnology | 2.37 | 142.39M | -5.58% | n/a | 11.57% |
| Vaxart Inc | VXRT | Biotechnology | 0.605 | 137.60M | -3.97% | n/a | 28.91% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 40.57 | 116.51M | -0.44% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.01 | 97.90M | 0.84% | 9.09 | 39.79% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 7.09 | 67.49M | 2.75% | n/a | 19.98% |
| ILAG | ILAG | Building Products & Equipment | 3.6016 | 65.04M | -4.21% | n/a | 5.48% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 9.37 | 58.67M | -0.64% | 14.48 | 7.10% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 19.59 | 29.83M | 25.34% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.11 | 16.22M | -2.63% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4275 | 8.26M | -0.47% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.71 | 4.37M | 1.18% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0063 | 580.95K | 12.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.98 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 16.12 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 73.33 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 138.06M | 3.66B | Emerging |